Cardiogenic shock - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Disease Reportscardiogenic shock

MeSH D012770 - cardiogenic shock

Favorite

Competitive Landscape

Events Timeline

Commercial

Clinical Trials

Competitive landscape

D009203:Myocardial infarction

$

Success rate

$

Success rate

Cardiogenic shock

$

Success rate

Events Timeline

5D

1M

3M

6M

YTD

1Y

2Y

5Y

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Plot placeholder

Mock data
Subscribe for the real data

Commercial

Company Name	Drug Name	Trade Name	Patent Expires	Approval Date	Revenue	Period
Eli Lilly	Glucagon	Baqsimi		2019-12-16	$652.8 M	Q2/23-Q3/24
Eli Lilly	Glucagon	Glucagon		1982-01-01

1

2

3

>

Clinical Trials

Historical Success Rate

Phase 1

0%

0/0

Phase 2

80%

4/5

Phase 3

47%

7/15

Approved: 4Overall Success rate: 0%

All Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Company name

Phase 1

Phase 2

Phase 3

Phase 4

Drug Name

1

2

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use